Mylène Jansen

SF biomarker changes upon KJD 335 16 Figure 4 : Association of change in synovial fluid analytes with the clinical outcome KOOS 4 . (A) Linear regression models for the association of the change over the distraction period for each of 10 synovial fluid analytes (measured in pg/ml) with participants’ change in KOOS 4 over varying periods are shown: upper panel, change in KOOS 4 over 3 months; middle panel, change in KOOS 4 over 6 months and lower panel, change in KOOS 4 over 12 months. Forest Plots of unadjusted (crude) results, including the regression coefficient for the effect on KOOS4 change over the specified period and 95% confidence intervals are shown. (B) The change of concentration in each analyte over the 6 week distraction period is shown, for clinical responders and non-responders. The bars represent the median and 95% confidence intervals for each group. Between group comparisons were by Mann-Whitney U test, * p= 0.04; ¥ p= 0.01. LTBP2, latent-transforming growth factor beta-binding protein 2; TGF β - 1, transforming growth factor beta 1; FGF-2, basic fibroblast growth factor; TIMP-1, tissue inhibitor of metalloproteinases 1; TSG-6, tumour necrosis factor-inducible gene 6 protein; IL-6: interleukin 6; MCP-1, monocyte chemoattractant protein 1; IL-8, interleukin 8; MMP3, matrix metalloproteinase-3; KOOS, Knee injury and Osteoarthritis Outcome Score (KOOS 4 is composite measure of 4 domains).